Salix Pharmaceuticals Announces the Publication of a Study Evaluating the Safety and Efficacy of UCERISÂ budesonide Tablets for Induction of Remission in Patients with Active Mild to Moderate Ulcerative Colitis Refractory to Mesalamine Therapy

BRIDGEWATER N.J. May 18 2017 PRNewswire Salix Pharmaceuticals today announced the peerreviewed publication of a study in the Journal of Crohn's & Colitis evaluating the safety and efficacy of budesonide multimatrix MMX which was examined for induc...